Skip to main content
    C

    Crispr Therapeutics AG (CRSP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $40.15
    -0.22 (-0.55%)

    Market Cap: $4.10B

    Last updated: Nov 17, 2026 at 4:36 PM ET

    Crispr Therapeutics AG (CRSP) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Crispr Therapeutics AG (CRSP) has a market cap of $4.10B and an enterprise value of $4.49B. It kept -1812.07% of revenue as net income over the last 12 months. Revenue fell 34.34% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 9.64% above the market cap, as debt exceeds cash.

    Market Cap$4.10B
    Enterprise Value$4.49B
    Latest price (Nov 17, 2026)$40.15

    Key Dates

    The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 10, 2027 (expected)
    Last Earnings DateNov 2, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.24% in the quarter ended Sep 30, 2026 and grew 6.54% a year over 2 years.

    Shares Outstanding96.74M
    Shares Change (YoY)+5.95%
    Shares Change (QoQ)+0.24%
    Share Count Growth (2Y CAGR)+6.54%

    Valuation Ratios

    Sales and book value multiples are 154.3x and 2.4x. Its year-end P/S ranged from 6.3x to 426.9x from 2016 to 2024.

    P/S Ratio154.3x
    Forward P/S115.5x
    P/B Ratio2.4x

    Valuation history and multiples

    Price Statistics

    The stock is down 23.57% over 52 weeks and trades 22.02% below its 50-day average.

    Beta (1Y)1.86
    52-Week Change-23.57%
    1-Month Change-19.76%
    3-Month Change-32.87%
    6-Month Change-15.63%
    5-Year Change-43.70%
    10-Year Change+181.75%
    Total Return (1Y)-23.57%
    Total Return (3Y CAGR)-16.06%
    Total Return (5Y CAGR)-13.52%
    Return vs SPY (1Y)-36.47%
    Max Drawdown (1Y)-35.13%
    Max Drawdown (3Y)-64.91%
    Sharpe Ratio (1Y)-0.50
    Correlation with SPY (1Y)0.44
    50-Day Average$51.49
    200-Day Average$52.42
    52-Week Range$39.83 to $63.45
    RSI (14 Days)28.9
    Average Volume (20 Days)1.78M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 16.21x current liabilities, and total debt is 0.36x shareholder equity.

    Current Ratio16.21x
    Quick Ratio16.21x
    Debt / Equity0.36x

    Returns and Efficiency

    Return on invested capital is -20.30% over the last 12 months, against a 5-year average of -30.07%.

    Return on Equity (ROE)-27.68%
    Return on Assets (ROA)-17.84%
    Return on Invested Capital (ROIC)-20.30%
    Return on Capital Employed (ROCE)-18.78%
    ROE (5Y Average)-15.26%
    ROA (5Y Average)-12.83%
    ROIC (5Y Average)-30.07%
    Asset Turnover0.01x

    Scores

    CRSP has an Altman Z-Score of 1.75, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score1.75
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $25.17M over the last 12 months.

    Revenue$25.17M
    Revenue Growth (YoY)-34.34%
    Gross Profit$25.17M
    Operating Income-$532.33M
    Pretax Income-$453.65M
    Net Income-$456.13M
    EBITDA-$434.41M
    EBIT-$453.65M
    Reported EPS (TTM)-$4.74

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 64.45% of the $2.56B in total assets.

    Cash and Equivalents$192.03M
    Total Debt$586.93M
    Net Debt$394.91M
    Net Debt Per Share$4.08
    Working Capital$2.14B
    Shareholder Equity$1.65B
    Book Value Per Share$17.04
    Total Assets$2.56B
    Total Liabilities$908.34M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $2.08M of capital spending, operating cash flow left -$376.71M of free cash flow.

    Operating Cash Flow-$374.63M
    Capital Expenditures$2.08M
    Free Cash Flow-$376.71M
    FCF Per Share-$3.90
    Depreciation and Amortization$19.23M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2114.75%.

    Gross Margin100.00%
    Operating Margin-2114.75%
    Pretax Margin-1802.19%
    Net Margin-1812.07%
    EBITDA Margin-1725.78%
    EBIT Margin-1802.19%
    FCF Margin-1496.56%

    Growth

    Revenue grew 43.09% a year over 3 years.

    Revenue Growth (3Y CAGR)+43.09%
    Revenue Growth (5Y CAGR)+37.31%
    Book Value Per Share Growth (2Y CAGR)-3.92%
    Tangible Book Per Share Growth (2Y CAGR)-3.92%

    Revenue and profit by year

    Dividends and Yields

    CRSP does not pay a dividend. Its free cash flow yield is -9.70%.

    FCF Yield-9.70%
    Buyback Yield-3.47%
    Shareholder Yield-3.47%

    Peer Position

    Against 8 similar companies, CRSP has the highest P/S.

    P/S Ratio154.3x vs 7.2x median
    ROIC-20.30% vs -29.31% median
    Revenue Growth (Trailing 4 Quarters, YoY)-34.34% vs -21.78% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 518.04% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+518.04%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CRSP

    What is CRSP's market cap?

    Crispr Therapeutics AG has a market cap of $4.10B. Its enterprise value, which adds debt and subtracts cash, is $4.49B.

    How many shares of CRSP are outstanding?

    Crispr Therapeutics AG has 96.74M shares outstanding. The count is up 5.95% from a year earlier.

    Does CRSP pay a dividend?

    No. Crispr Therapeutics AG does not pay a dividend.

    How much debt does CRSP have?

    Crispr Therapeutics AG has $586.93M of total debt and $192.03M of cash and equivalents, a net debt position of $394.91M.